OverviewChartNewsTraderScreen

Morgan Stanley Call 80 NOVN 19.12.../  DE000MG1WJA0  /

Stuttgart
2024-07-31  8:32:17 PM Chg.- Bid10:00:33 PM Ask10:00:33 PM Underlying Strike price Expiration date Option type
2.15EUR - -
Bid Size: -		 -
Ask Size: -		 NOVARTIS N 80.00 CHF 2025-12-19 Call
TeleTrader 07-18 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 06-26 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 06-13 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
TeleTrader 05-02 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 04-23 Novartis up 5% on upbeat guidance, earnings
TeleTrader 04-23 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 04-16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 04-09 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 03-14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 02-28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B
TeleTrader 01-31 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 01-10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 01-05 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire 2023-12-19 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire 2023-12-11 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire 2023-12-08 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire 2023-12-06 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
TeleTrader 2023-11-28 Novartis expects 5% annual sales growth until 2027
GlobeNewswire 2023-11-20 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH